Temozolomide alone or combined to capecitabine for the treatment of advanced pancreatic NET
Introduction: Combining capecitabine (CAP) to temozolomide (TEM) chemotherapy in advanced pancreatic neuroendocrine tumors (PanNET) relies on limited evidences. We compared TEM-CAP to TEM alone in patients with advanced PanNET.
Methods: Consecutive patients with advanced PanNET treated by TEM or TEM-CAP between 2004 and 2017 in three expert centers were included. Progression-free survival (PFS), tolerance, tumor response and overall survival were compared between the two groups. Propensity-based analyses were performed to reduce confounding bias due to the nonrandomized setting.
Results: TEM and TEM-CAP were administered in 38 patients and 100 patients, respectively, of median age 58 years. Patients in the TEM group had more functioning syndrome (p=0.03), longer median delay from diagnosis (p=0.001) and heavier pretreatment (p
Source: Neuroendocrinology - Category: Endocrinology Source Type: research